Halozyme to Report Second Quarter 2024 Financial and Operating Results
Halozyme Therapeutics (NASDAQ: HALO) has announced the upcoming release of its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, after the market closes. The company will host a conference call on the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors and interested parties can pre-register for the call using a provided link. Additionally, a live webcast and replay of the conference call will be available through the "Investors" section of Halozyme's corporate website.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato il rilascio dei suoi risultati finanziari e operativi del secondo trimestre 2024 previsto per martedì 6 agosto 2024, dopo la chiusura del mercato. L'azienda terrà una conference call lo stesso giorno alle 13:30 PT/16:30 ET per discutere i risultati. Gli investitori e le parti interessate possono preregistrarsi per la chiamata utilizzando un link fornito. Inoltre, sarà disponibile un webcast in diretta e una registrazione della conference call nella sezione 'Investitori' del sito web aziendale di Halozyme.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado el próximo lanzamiento de sus resultados financieros y operativos del segundo trimestre de 2024 el martes 6 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica el mismo día a la 1:30 p.m. PT/4:30 p.m. ET para discutir los resultados. Los inversores y partes interesadas pueden preregistrarse para la llamada utilizando un enlace proporcionado. Además, habrá una transmisión en vivo y una repetición de la conferencia telefónica disponibles a través de la sección 'Inversores' en el sitio web corporativo de Halozyme.
Halozyme Therapeutics (NASDAQ: HALO)는 2024년 2분기 재무 및 운영 결과를 2024년 8월 6일 화요일, 시장이 마감된 후 발표할 예정이라고 발표했습니다. 회사는 같은 날 오후 1시 30분 PT/오후 4시 30분 ET에 결과를 논의하기 위한 컨퍼런스 콜을 진행합니다. 투자자 및 관심이 있는 분들은 제공된 링크를 통해 미리 등록할 수 있습니다. 또한, Halozyme의 기업 웹사이트 '투자자' 섹션을 통해 실시간 웨비나 및 컨퍼런스 콜 재생이 제공될 것입니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé la prochaine publication de ses résultats financiers et opérationnels du deuxième trimestre 2024 le mardi 6 août 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique le même jour à 13h30 PT/16h30 ET pour discuter des résultats. Les investisseurs et les parties intéressées peuvent se préinscrire pour l'appel en utilisant un lien fourni. De plus, un webinaire en direct et une rediffusion de la conférence téléphonique seront disponibles dans la section 'Investisseurs' du site web corporatif de Halozyme.
Halozyme Therapeutics (NASDAQ: HALO) hat die bevorstehende Veröffentlichung seiner Finanz- und Betriebsergebnisse für das zweite Quartal 2024 am Dienstag, den 6. August 2024, nach Börsenschluss angekündigt. Das Unternehmen wird am selben Tag um 13:30 Uhr PT/16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren. Investoren und Interessierte können sich über einen bereitgestellten Link für den Anruf vorregistrieren. Darüber hinaus wird ein Live-Webcast und die Wiederholung der Telefonkonferenz im Bereich 'Investoren' der Unternehmenswebseite von Halozyme verfügbar sein.
- None.
- None.
Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of reducing treatment burden for patients. Having touched more than 800,000 patient lives in post-marketing use in eight commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-second-quarter-2024-financial-and-operating-results-302203593.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (HALO) release its Q2 2024 financial results?
What time is Halozyme's (HALO) Q2 2024 earnings call scheduled for?
How can investors access Halozyme's (HALO) Q2 2024 earnings call?
Will there be a replay available for Halozyme's (HALO) Q2 2024 earnings call?
